XML 70 R56.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
segment
Mar. 31, 2024
USD ($)
Segment Reporting    
Number of operating segments | segment 1  
Revenue $ 10,698 $ 14,774
Cost of product revenue 1,262 1,326
Research & Development    
Stock-based compensation 10,456 7,978
Depreciation 981 920
Interest income 3,826 3,922
Interest expense (2,984) (4,051)
Loss from debt extinguishment   (27,950)
Net Income (Loss) (64,053) (64,848)
Single Reportable Segment    
Segment Reporting    
Revenue 10,698 14,774
Cost of product revenue 1,262 1,326
Research & Development    
Direct program expenses, AXPAXLI for wet AMD 24,455 5,493
Direct program expenses, Other clinical and preclinical programs 1,081 3,215
Unallocated expenses, Personnel costs 8,983 7,128
Unallocated expenses, All other costs 3,255 802
Selling and marketing 12,817 9,262
General and administrative 9,661 8,344
Facilities 1,664 1,923
Stock-based compensation 10,456 7,978
Depreciation 981 920
Interest income 3,826 3,922
Interest expense (2,984) (4,051)
Loss from debt extinguishment   (27,950)
Other non-operating items (978) (5,152)
Net Income (Loss) $ (64,053) $ (64,848)